Adjunctive pharmacotherapy for coronary stenting

Citation
Sa. Harding et al., Adjunctive pharmacotherapy for coronary stenting, CURR OPIN C, 16(5), 2001, pp. 293-299
Citations number
75
Language
INGLESE
art.tipo
Review
Categorie Soggetti
Cardiovascular & Respiratory Systems
Journal title
CURRENT OPINION IN CARDIOLOGY
ISSN journal
0268-4705 → ACNP
Volume
16
Issue
5
Year of publication
2001
Pages
293 - 299
Database
ISI
SICI code
0268-4705(200109)16:5<293:APFCS>2.0.ZU;2-J
Abstract
The use of coronary stents improves the outcomes of percutaneous coronary i ntervention (PCI). This has led to a rapid increase in their use. Coronary stenting is not without problems and is complicated by both early ischemic events and late restenosis. The combination of anticoagulation with unfract ionated heparin (UFH) and the use of antiplatelet agents including aspirin, thienopyridines, and glycoprotein IIb/IIIa inhibitors has led to a major r eduction in early ischemic events after stenting. Low molecular weight hepa rin (LMWH) and direct thrombin inhibitors have a number of theoretical adva ntages over UFH. Their role as an adjunct to coronary stenting is still und er investigation. Trials of systemic pharmacotherapy aimed at reducing in-s tent restenosis have been consistently disappointing. Preliminary results o f stents coated with agents that inhibit neointimal proliferation are extre mely promising. The results of ongoing phase III trials of these coated ste nts are eagerly awaited. (C) 2001 Lippincott Williams & Wilkins, Inc.